

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shaanxi Micot Pharmaceutical Technology Co., Ltd.

陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02335)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Friday, 28 August 2026, for the purposes of, among other matters, approving the unaudited interim results of the Company and its subsidiaries for the six months ended 30 June 2026 and its publication, considering the payment of an interim dividend (if any), and transacting any other business.

By order of the Board

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Dr. Wang Bing

Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 14 August 2026

As at the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.